Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Via P. Valdoni 7, 34100, Trieste, Italy.
Cardiothoracic Department, Center for Diagnosis and Treatment of Cardiomyopathies, Institute of Pathological Anatomy and Histology, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.
Heart Fail Rev. 2023 Jan;28(1):123-135. doi: 10.1007/s10741-022-10247-5. Epub 2022 May 14.
Endomyocardial biopsy (EMB) is an invasive procedure originally developed for the monitoring of heart transplant rejection. Over the year, this procedure has gained a fundamental complementary role in the diagnostic work-up of several cardiac disorders, including cardiomyopathies, myocarditis, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumours. Major advances in EMB equipment and techniques for histological analysis have significantly improved diagnostic accuracy of EMB. In recent years, advanced imaging modalities such as echocardiography with three-dimensional and myocardial strain analysis, cardiac magnetic resonance and bone scintigraphy have transformed the non-invasive approach to diagnosis and prognostic stratification of several cardiac diseases. Therefore, it emerges the need to re-define the current role of EMB for diagnostic work-up and management of cardiovascular diseases. The aim of this review is to summarize current knowledge on EMB in light of the most recent evidences and to discuss current indications, including challenging scenarios encountered in clinical practice.
心肌内膜活检(EMB)是一种侵入性程序,最初用于监测心脏移植排斥反应。多年来,该程序在多种心脏疾病的诊断中发挥了基本的补充作用,包括心肌病、心肌炎、药物相关性心脏毒性、淀粉样变性、其他浸润性和储存性疾病以及心脏肿瘤。EMB 设备和组织学分析技术的重大进步显著提高了 EMB 的诊断准确性。近年来,超声心动图三维和心肌应变分析、心脏磁共振和骨闪烁显像等先进的影像学方式改变了几种心脏病的诊断和预后分层的非侵入性方法。因此,有必要重新定义 EMB 在心血管疾病诊断和管理中的当前作用。本篇综述的目的是根据最新证据总结 EMB 的当前知识,并讨论当前的适应证,包括临床实践中遇到的具有挑战性的情况。